All the news Showing 10 of 40 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis B treatment for all who need it an "achievable public health goal" for Malawi Keith Alcorn / 13 December 2021 Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ... 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Hepatitis B antiviral drugs reduce liver cancer risk Liz Highleyman / 19 November 2019 Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ... Tenofovir may lower the risk of liver cancer more than entecavir Liz Highleyman / 18 April 2019 People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ... Core protein inhibitor shows promising activity against hepatitis B Liz Highleyman / 16 April 2019 An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ... Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... New simplified scoring system identifies people with hepatitis B in need of treatment in Africa Keith Alcorn / 02 July 2018 Liver enzyme and hepatitis B 'e' antigen test results are sufficient to determine which people with hepatitis B need antiviral treatment for the infection in sub-Saharan Africa, a study carried ... ← First123...4Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive